 |
|
|---|---|
| Systematic (IUPAC) name | |
| (5R,11S)- 13-amino- 5-methyl- 5,6,7,8,9,10,11,12-octahydro- 5,11-methanobenzo[10]annulen- 3-ol | |
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Half-life | 2.2 hours |
| Identifiers | |
| CAS number | 53648-55-8  |
| ATC code | N02AX03 |
| PubChem | CID 3033053 |
| DrugBank | DB01209 |
| ChemSpider | 2297867 |
| UNII | VHX8K5SV4X |
| KEGG | D00838 |
| ChEBI | CHEBI:4474 |
| ChEMBL | CHEMBL1685 |
| Synonyms | WY-16,225 |
| Chemical data | |
| Formula | C16H23NO |
| Mol. mass | 245.36 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Dezocine (Dalgan) was developed by American Home Products[1] and is an opioid analgesic related to pentazocine, with a similar profile of effects that include analgesic action and euphoria at low doses,[2] but produces dysphoria and hallucinations at high doses, most likely due to action at κ-opioid receptors.[3][4]
Dezocine has been found to be an effective painkiller comparable to meperidine (pethidine),[5] and so is a more effective analgesic than pentazocine, but causes relatively more respiratory depression than pentazocine.[6] It is a useful drug for the treatment of pain,[7] but side effects such as dizziness limit its clinical application,[8] and it can produce opioid withdrawal syndrome in patients already dependent on other opioids.[9]
Dezocine is unusual among opioids as it is one of the only primary amines known to be an active opioid (along with bisnortilidine, an active metabolite of tilidine). It is a mixed agonist-antagonist as with other drugs in this class,[10] and despite having a stronger respiratory depressant effect than morphine, dezocine shows a ceiling effect on its respiratory depressive action so above a certain dose this effect does not get any more severe.[11]
See also [link]
References [link]
- ^ DE patent 2159324
- ^ Zacny, J. P.; Lichtor, J. L.; de Wit, H. (1992). "Subjective, Behavioral, and Physiologic Responses to Intravenous Dezocine in Healthy Volunteers". Anesthesia and Analgesia 74 (4): 523–530. PMID 1348168.
- ^ Jacobs, A. M.; Youngblood, F. (1992). "Opioid Receptor Affinity for Agonist-Antagonist Analgesics". Journal of the American Podiatric Medical Association 82 (10): 520–524. PMID 1361946.
- ^ Gharagozlou, P.; Hashemi, E.; DeLorey, T. M.; Clark, J. D.; Lameh, J. (2006). "Pharmacological Profiles of Opioid Ligands at Kappa Opioid Receptors" (pdf). BMC Pharmacology 6: 3. DOI:10.1186/1471-2210-6-3. PMC 1403760. PMID 16433932. https://www.biomedcentral.com/content/pdf/1471-2210-6-3.pdf.
- ^ Camu, F.; Gepts, E. (1979). "Analgesic Properties of Dezocine for Relief of Postoperative Pain". Acta Anaesthesiologica Belgica 30 (Suppl): 183–191. PMID 398127.
- ^ Wuest, H. P.; Bellville, J. W. (1979). "The Respiratory Effects of Dezocine and Pentazocine in Man". Journal of Clinical Pharmacology 19 (4): 205–210. PMID 438355.
- ^ O'Brien, J. J.; Benfield, P. (1989). "Dezocine. A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy". Drugs 38 (2): 226–248. PMID 2670517.
- ^ Oosterlinck, W.; Verbaeys, A. (1980). "Preliminary Clinical Experience with Dezocine, a New Potent Analgesic". Current Medical Research and Opinion 6 (7): 472–474. PMID 7363647.
- ^ Strain, E. C.; Preston, K. L.; Liebson, I. A.; Bigelow, G. E. (1996). "Opioid Antagonist Effects of Dezocine in Opioid-Dependent Humans". Clinical Pharmacology and Therapeutics 60 (2): 206–217. PMID 8823239.
- ^ Young, A. M.; Stephens, K. R.; Hein, D. W.; Woods, J. H. (1984). "Reinforcing and Discriminative Stimulus Properties of Mixed Agonist-Antagonist Opioids". Journal of Pharmacology and Experimental Therapeutics 229 (1): 118–126. PMID 6142942.
- ^ Romagnoli, A.; Keats, A. S. (1984). "Ceiling Respiratory Depression by Dezocine". Clinical Pharmacology and Therapeutics 35 (3): 367–373. PMID 6421529.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
